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ABSTRACT
We present an overview of protein and peptide compounds confiscated in Denmark from late 2007 till late 2013 together with a 
description of a newly developed HRAM-LC-MS method used for identification. As examples of identification, we present data for the 
peptides AOD-9604, [D-Ala2, Gln8, Ala15, Leu27]sermorelin and the protein follistatin. It was found that a method with minimum sample 
preparation could be implemented for all of the confiscated peptides and the protein somatropin. However, for the protein follistatin it 
was necessary to include trypsin digestion in the sample preparation, which considerably increases the overall analysis time.
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ABBREVIATIONS
LC   - Liquid Chromatography, 
HRAM-MS  - High-Resolution Accurate Mass - Mass Spectrometry, 
FWHM - Full Width Half Maximum
1. INTRODUCTION
In recent years the pharmaceutical industry has increased the number 
of proteins and peptides on the market and additional compounds are in 
research and development phases [1,2]. This development also influences 
the type of drugs found on the illegal market. Protein and peptide drugs, 
especially those relevant for doping in sports, are often confiscated, including 
compounds that are not available on the legal, pharmaceutical market [3]. 
This not only represents a problem in terms of cheating in sports but also 
constitutes a health issue, since the compounds are not guaranteed to be 
of pharmaceutical grade quality, and in many cases have not been licensed 
for human consumption, or have even failed clinical trials. An example of the 
latter is the peptide drug cjc-1295 [4], which was discontinued in phase II 
clinical trials following the death of a test person [5,6], but is still advertised 
for sale on the black market.
The protein and peptide compounds confiscated in Denmark are 
usually identified by Danish customs or police as being doping related based 
on their visual appearance; injections vials containing either a powder or in 
some cases a liquid. Often the vials are labeled with a compound name, in 
which case the legal authorities often choose to not have the compound 
analyzed further. In other cases the vials are delivered to our department 
for identification. If the compound is not present in our in-house database, 
it is either analyzed further by us or forwarded to specialized doping control 
institutions in Norway or Germany and subsequently added to the database. 
The in-house database is continuously created using reference compounds. 
The reference compounds are either from trusted manufactures or from 
confiscated compounds, which has been identified by other accredited 
institutions or by us as demonstrated in this paper for the compounds AOD-
9604 and follistatin.
To identify the compounds we employ two complimentary methods: i) 
First the compound is analyzed by HPLC-DAD and the retention time and UV-
profile are compared to our internal database. ii) The compound is analyzed 
with HRAM-LC-MS for added certainty in the identification. For identification 
of peptides and proteins by HRAM-LC-MS we use a combination of accurate 
mass determination, retention time and characteristic product ions. This 
approach is based on the recommendations put forward by Thevis et al. 
for identification of peptides and proteins in doping control [7]. The aim of 
this paper is to describe the newly developed HRAM-LC-MS method and 
to present an overview of the compounds encountered by our forensic 
laboratory between 2007 and 2013.
2. MATERIALS AND METHODS
The confiscated injection vials all contained white powder material. The 
powders were dissolved in water to a final concentration of a few mg/ml. 
Water and acetonitrile used were both LC-MS grade (Fischer Scientific, UK). 
Formic acid was 98-100% (Merck KGaA, Germany).
2.1 HPLC-DAD
High-Performance Liquid Chromatography with Diode-Array Detection 
(HPLC-DAD) separation was performed on an YMC-Pack PROTEIN-RP 
column (YMC Europe GmbH, Germany) held at a temperature of 30 °C, 
with UV-detection at 210 nm (scan range 210-400 nm). The mobile phase 
was composed of solvents A (0.5% TFA in mili-Q water), B (acetonitrile) 
and C (mili-Q water) the flow rate was 1.0 ml/min and an injection volume 
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of 10 µL. The gradient was isocratic for 5 min at: (A: 20%, B: 10%, C: 70%), 
increased to (A: 20%, B: 70%, C: 10%) during 35 min, and was subsequently 
re-equilibrated for 5 min.
2.2 HRAM-LC-MS/MS
In the HRAM-LC-MS/MS method chromatographic separation was performed 
on a Dionex Ultimate 3000 UHPLC system (Thermo Scientific, Germany) with 
an Acclaim® PepMap100 C18, 3µm, 100Å column (1.0 mm x 15 cm), (Thermo 
Scientific, US), which was maintained at a temperature of 40 °C. The mobile 
phase was composed of solvents A (water containing 0.1% formic acid) 
and B (acetonitrile and 0.1% formic acid) at a flow rate of 0.06 mL/min. The 
gradient had a total run-time of 30 min starting at 5 % B increasing to 95 
% B over 25 min, isocratic for 2 min before re-equilibration for 3 min. The 
injection volume was 5-10 µL.
The LC was coupled to a Q-Exactive mass spectrometer (Thermo 
Scientific, Germany) using positive electrospray ionization, with a cone 
voltage of 4 kV and capillary temperature of 200°C.  The data were acquired 
using data-dependent acquisition with MS/MS scans of the top 5 most 
abundant ions after each full scan. Full scan data were collected in profile 
mode from m/z 280-2000 at a resolution of 70,000 (FWHM @ m/z 200). 
Normalized collision energy of 20% was used to create the product ions, 
which were detected at a resolution of 35.000. The Q-Exactive was externally 
calibrated in positive and negative mode twice a week using Pierce® ESI 
positive and negative calibration solutions (Thermo Scientific, US).
2.2.1 Reduction of disulfide bonds and cysteine alkylation
0.5 mg of protein or peptide powder was dissolved in 100 µl buffer (50mM 
ammonium bicarbonate). The disulfide bonds were then reduced by adding 
10 µl 100 mM dithiothreitol solution (Sigma, US) and heated to 95°C for 15 
min. The reduced cysteine groups were subsequently alkylated by adding 10 
µl of freshly prepared iodoacetamide (Sigma, US) solution (200mM in water), 
and placed in the dark at room temperature for 30 min.
2.2.2 Trypsin treatment
The solution of alkylated protein was then diluted with 500 µl ammonium 
bicarbonate buffer before addition of 100 µl (50 mM acetic acid in water, pH 
8) containing 2.5 µg sequencing grade trypsin (Promega, US). The solution 
was incubated at 37 °C for 16 hours. The trypsin to protein powder mass ratio 
was 1:200.
3. RESULTS
The peptide and protein drug substances confiscated by Danish customs 
and police in the period between late 2007 and late 2013 are presented 
in Table 1. The identified compounds totaled 6 different peptides (AOD-
9604, GHRP-2, GHRP-6, sermorelin, [D-Ala2, Gln8, Ala15, Leu27]sermorelin and 
melanotan II) and 4 proteins (somatropin, hCG, follistatin and IGF-1).
3. 1 AOD-9604
AOD-9604 is a 16 amino acid fragment of the C-terminus of the growth 
hormone protein Somatropin. It has a monoisotopic molecular mass of 
1813.8604 Da, and the amino acid sequence: YLRIVQCRSVEGSCGF with a 
disulfide bridge between the cysteines at position 7 and 14 (see Figure 1). 
The disulfide bond can be reduced with DTT and the reduced cysteine groups 
alkylated with iodoacetamide to prevent reformation of the disulfide bonds, 
giving a monoisotopic weight of alkylated AOD-9604 of 1929.9189 Da.
The first criteria for successful identification of AOD-9604 is the 
observation of the precursor ions corresponding to the mass 1813.8604 Da 
Table 1. Substances identified in confiscated products by our department during the period 2007-2013.
 
Year
20071 2008 2009 2010 2011 2012 20131




Sermorelin 1 1 3
[D-Ala2, Gln8, Ala15, 
Leu27] Sermorelin
7 2 1
Melanotan II 3 1 6 1
Follistatin 1
Somatropin 2 2 7 7 2 1
hCG 1 2 2 3 1 1
IGF-1 1 12
Negatives 1 1 2 4 4 33
1 From late 2007 and first half of 2013, respectively
2 Presumed to be IGF-1 from the original label and from initial HPLC-DAD analysis, but later found to be negative
3 In one of the cases (10 vials) the label was said to contain somatropin
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and 1929.9189 Da for the untreated and alkylated peptide, respectively. In 
the MS spectra of both alkylated and non-alkylated AOD-9604, two charge 
states are observed (see inserts in Figure 2 and 3) that both correspond to 
the expected mass of the peptide. The second criteria is the observation of 
the expected product ions from fragmentation: The MS/MS of the double 
charged AOD-9604 ions produces the product ions seen in Figure 2 and 3.
3. 2 [D-Ala2, Gln8, Ala15, Leu27]sermorelin
The amino acid sequence of this sermorelin analogue is 
YADAIFTQSYRKVLAQLSARKLLQDILSR-NH2, where the second alanine, 
Ala2, is the non-natural D-isomer. This peptide was identified by its 
retention time and UV-spectrum on the HPLC-DAD method and from its 
characteristic precursor and product ions on the HRAM-LC-MS. [D-Ala2, 
Gln8, Ala15, Leu27]sermorelin has a calculated monoisotopic weight of 
3365.8936 Da and 6 chargeable groups (3 arginine and 2 lysine amino 
acids, plus the amino group at N-terminal). A primary identification 
criterium is therefore the presence of at least some of the ions 
corresponding to the 6 positively charged species: [M+H]1+ to [M+6H]6+ 
(see Figure 4). Secondly, the observed precursor ions are fragmented 
to produce characteristic product ions for further identification 
(see Figure 5 and 6).
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Figure 3. Mass spectrum of alkylated AOD-9604 product ions (precursor 644.3 m/z). The b-ions b8
2+ to b13
2+ is only observed in the treated AOD-9604 since the di-






Figure 4. Mass spectrum of [D-Ala2, Gln8, Ala15, Leu27]Sermorelin precursor 







A confiscated injection vial labeled as follistatin was investigated by HRAM-
LC-MS. No peptides or proteins were initially detected in the untreated 
sample, which was therefore reduced, alkylated and treated with trypsin 
before it was re-analyzed. The chromatogram now revealed several smaller 
peptides indicating that a protein had been present. Based on the label, 
the amino acid sequence of both follistatin-288 and follistatin-315 were 
examined for trypsin cleavage sites. Since trypsin cleaves the polypeptide 
chain at specific sites (after arginine and lysine, if either is not followed 
directly by proline) the expected peptides can be predicted (see the tryptic 
peptides in Figure 7). Since arginine and lysine are both positively charged 
amino acids, most peptides will be double charged ions [M+2H]+2.
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4. DISCUSSION
The detection and identification of peptides and proteins is an 
interdisciplinary field. In proteomics the challenge is usually to identify 
hundreds or thousands of different proteins in a mixture at low 
concentrations, a process in which the mix of proteins is digested to 
form smaller peptides that are then analyzed against huge databases. In 
doping control, the task is to identify one or more peptides or proteins in 
a biological matrix. In contrast, confiscated drugs are usually in a relatively 
pure state,  though some examples of mixtures are encountered, e.g. doping 
related peptides found in nutritional supplements [3], and confiscated vials 
containing more than one drug compound.
Examples of LC-MS characterization of doping peptides and proteins: 
GHRP-2 [3,9,10], GHRP-6 [10], sermorelin [11], [D-Ala2, Gln8, Ala15, Leu27]
sermorelin [12], melanotan II [13-15], IGF-1 [16-19], hCG [20,21] and 
somatropin [11,19]. Mass spectrometry data for identification of AOD-9604 
and follistatin has to our knowledge not previously been published in the 
literature and is therefore presented here. Identification of [D-Ala2, Gln8, Ala15, 
Leu27]sermorelin using LC-MS/MS was recently published [12], but here we 
identify this peptide without prior treatment with trypsin.
With the HPLC-DAD method all of the above compounds are detectable, 
though the larger proteins have to be flushed from the column with an 
organic:aqueous phase ratio of 80:20. On the HRAM-LC-MS method all the 
above peptides and somatropin where directly detectable. As there were no 
recent samples of IGF-1 and hCG available at the time, these were not tested 
on the HRAM-LC-MS method. 
Follistatin had to be enzymatically digested into smaller peptides before 
being observable on the MS. This could have a number of explanations. 
Many proteins, especially large proteins with a low structural stability, adsorb 
strongly and practically irreversible on most surfaces. Therefore the amount 
of protein that elutes from the column is severely limited. Furthermore, 
large molecules are a lot less likely to turn into gas form in the electrospray 
interface [8].
For peptides at low collision energies, as used in these experiments, 
the observed MS/MS fragments mostly correspond to a break of the 
peptide backbone at the bond between the carbonyl carbon and the amine 
nitrogen. The fragment on the N-terminal is designated as the b-ion and the 
fragment on the C-terminal side of the cleavage is the y-ion according to 
nomenclature. This is depicted with AOD-9604 as an example in Figure 1.
4.1 AOD-9604
This peptide was initially developed as an anti-obesity drug and was recently 
the focus of a large doping scandal in Australian Rules football. It is not 
licensed for pharmaceutical distribution, but products using the name is 
marketed and sold online as a fat-burning and muscle building drug.
The disulfide bond in the molecule prevents the formation of identifiable 
ions between position 7 and 14 in the chain. For example a break of the 
peptide bond between #8-9 would have the same m/z as that between 
e.g. #9-10 (see Figure 1). Because AOD-9604 was not in our database and 
because detailed mass spectral data has not been previously published, we 
decided to do a more thorough identification to include identifying ions 
between these positions. This is done by reducing the disulfide bond and 
alkylating the reduced cysteine side-group.
Both the alkylated and non-alkylated samples produce species with two 
and three charges (Figure 2 and 3). These three charges most likely reside 
on the N-terminal amino-group and the arginine amino acids at position 3 
and 8, as they are the most ionizable groups of the molecule. In the MS/MS 
spectrum of alkylated AOD-9604 a range of b- and y-ions are formed that 
are not observed in the untreated AOD-9604 (Figure 3). This demonstrates 
that the compound was indeed AOD-9604 linked with an internal disulfide 
bond. To minimize preparation time in the future, our identification will be 
based on the precursor and product ions from the untreated, non-alkylated 
peptide. This identification is done from molecular weight determination 
from the two precursor ions and structural identification from a total of 12 
product ions with assignment as seen in Table 2.
4.2 [D-Ala2, Gln8, Ala15, Leu27]Sermorelin
In 2005 the Canadian company ConjuChem published a number of modified 
versions of the growth-releasing-factor peptide sermorelin, named CJC-1288, 
CJC-1293 and CJC-1295 [4]. These modifications all included the addition of 
a lysine at the C-terminus linked to a chemical group named “Drug Affinity 
Construct” (DAC) by the company [4]. These peptide drugs are no longer 
in the pipeline at ConjuChem, but compounds using these names can be 
bought online from other sources. However, these products have mostly 
been found by our laboratory and others [12] to contain sermorelin or the 
modified sermorelin lacking the lysine-linker and DAC-group, a peptide for 
which the IUPAC name would be [D-Ala2, Gln8, Ala15, Leu27]sermorelin.
[D-Ala2, Gln8, Ala15, Leu27]sermorelin was identified from the molecular 
weight calculated from precursor ions and from structural information from 
product ions, as seen in Table 3.
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It is an interesting observation that for most of the peptides and 
proteins the fragmentation pattern is very dependent on the choice of 
precursor ion. For example compare the product ions of [D-Ala2, Gln8, Ala15, 
Leu27]sermorelin having +3 and +6 charges (Figures 5 and 6). The most 
apparent difference is that for the low charge, the fragments have a lot 
lower abundance (notice the scale of the y-axis). The most abundant ion 
here is the unfragmented precursor ion itself at m/z 1122.97 and the most 
abundant fragment is only 1%. In contrast, the MS/MS from the +6 precursor 
(m/z 561.99) is much more fragmented and fragments have higher relative 
intensities. As seen by comparison of Figures 5 and 6 the precursor ion with 
more charges produces more and smaller fragments. On the contrary, many 
of the larger b- and y-ions can be detected in the MS/MS of the low charge 
precursor. Analytically this has the advantage that a larger range of product 
ions can be detected. Thus we generally base identification on a range of 
precursor ions (see for example Table 3).
4.3 Follistatin
Follistatin exists in two isoforms of either 288 amino acids or 315 amino 
acids, which can be post-translationally N-glycosylated at positions Asn95 
and Asn259. There seems to be little focus on follistatin in the academic 
doping and forensic literature, but the product is widely sold on the internet 
and is especially advertised for body building.
Follistatin was identified by detection of peptide fragments after 
treatment with trypsin. The observed peptides cover at least 85% of the 
total sequence. The parts of the sequence that are not covered consist of 
the very small tryptic peptides, 1-3 amino acid length, and the C-terminal 
peptide (T41 in Figure 7). Follistatin has a high frequency of arginine and 
lysine amino acids, resulting in many cleavages and small peptides that are 
difficult to separate on the column and identify. To distinguish between 
follistatin-288 and -315 the C-terminal peptide would be detected as either a 
sequence of length 6 or 33, respectively. While one should expect to detect 
the follistatin-288 C-terminal the follistatin-315 C-terminal peptide is a very 
long sequence and does not contain an arginine or lysine in the end. A low 
charge and a long sequence make this peptide unlikely to be efficiently 
ionized and thus detected with MS [8]. This suggests that the protein was 
follistatin-315, though further analysis would be needed to conclusively 
distinguish it from follistatin-288. The tryptic peptides containing position 
95 (peptide T16) and position 259 (peptide T39) where both detected at the 
mass expected from their amino acid sequence, suggesting that none of the 
N-glycosylation sites were glycosylated. The lack of glycosylation suggests 
that the compound is a recombinant follistatin that has been expressed in a 
bacterial cell culture.
4.4 Confiscated drugs
We note that the original labels on the confiscated products do not 
necessarily correspond with the actual substance found from analysis. So far, 
all of the products sold under the names cjc-1295 and cjc-1293 contained 
Table 2. Identification of AOD-9604 by HRAM-LC-MS/MS. Two precursor ions 
are observed at m/z 907.9357 and m/z 605.6270, respectively. Each produces 
fragment ions, which are used for further certainty in the identification. Mas-
ses are for the monoisotopic molecules.
 
Precursor ions
Fragment ions (M+2) m/z 907.9357
(M+3) m/z 
605.6270
Fragment ion 1 (m/z) 136.076 b1 - immonium ion 796.889 b14
2+
Fragment ion 2 (m/z) 277.155 b2 825.399 b15
2+
Fragment ion 3 (m/z) 433.256 b3
Fragment ion 4 (m/z) 546.340 b4
Fragment ion 5 (m/z) 645.409 b5
Fragment ion 6 (m/z) 773.467 b6
Fragment ion 7 (m/z) 166.087 y1
Fragment ion 8 (m/z) 223.108 y2
Fragment ion 9 (m/z) 1042.409 y10
Fragment ion 10 (m/z) 1170.467 y11
MW (Da) 1813.86
 
Table 3. Identification of [D-Ala2, Gln8, Ala15, Leu27]Sermorelin by HRAM-LC-MS/MS. A total of four different precursor ions are used. Product ions of these precur-
sors are detected for further certainty in the identification. Masses are for the monoisotopic molecules.
 
Precursor ions
Fragment ions (M+3)  m/z 1122.97 (M+4) m/z 842.48 (M+5) m/z 674.19 (M+6) m/z 561.99
Fragment ion 1 (m/z) 1068.615 y28
3+ 699.931 y12
2+ 235.108 b2 235.108 b2
Fragment ion 2 (m/z) 1044.939 y27
3+ 856.021 y15
2+ 350.135 b3 350.135 b3
Fragment ion 3 (m/z) 1006.591 y26
2+ 962.097 y17
2+ 421.172 b4 421.172 b4
Fragment ion 4 (m/z) 487.336 y4 819.831 y21
3+ 534.256 b5 534.256 b5
Fragment ion 5 (m/z) 1440.7907 b25
2+ 896.200 y23
3+ 681.325 b6 681.325 b6
Fragment ion 6 (m/z) 945.223 y24
3+ 374.252 y3 261.168 y2
Fragment ion 7 (m/z) 982.918 y25
3+ 487.336 y4 374.252 y3
Fragment ion 8 (m/z) 1006.597 y26
3+ 602.363 y5 487.336 y4
Fragment ion 9 (m/z) 1044.939 y27
3+ 956.589 y8
Fragment ion 10 (m/z) 1068.618 y28
3+ 1084.684 y9
MW (Da) 3365.894
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sermorelin or the tetra substituted analogue [D-Ala2, Gln8, Ala15, Leu27]
sermorelin. In some cases the products do not appear to contain any drug 
substance or contain an undetectable level of drug.
It is a noticeable trend (Table 1) that from the year 2011 and onwards, 
a number of new doping agents appear: AOD-9604, GHRP-2, GHRP-6, 
sermorelin, [D-Ala2, Gln8, Ala15, Leu27]sermorelin and follistatin. This is 
probably due to the fact that from 2010 Danish customs decided to increase 
their focus on the import of doping related drugs. Indeed, since late 2010 
by far most of the seizures are confiscated by the customs, not the police. 
Another common denominator between these compounds is their presence 
on the internet on body building forums and advertising. It would seem that 
the new focus from Danish customs has revealed that a large amount of 
drugs are bought on the internet. Since the 1st of January 2014 the penalty 
for doping offenses in Denmark increased from two to six years, which 
equates Danish law with the law of the surrounding countries [22]. This also 
expands the range of possible measures for the police to investigate and 
intervene in such cases, possibly leading to more cases in the future.
5. CONCLUSION
In conclusion a HRAM-LC-MS method was developed which, with minimum 
sample preparation, could identify all encountered peptide compounds 
and the protein somatropin, using precursor ions and fragments. It was 
not possible to identify the protein follistatin with this method, therefore 
a different approach using trypsin digestion and subsequent identification 
of characteristic tryptic peptides was used. These methods supplement 
our HPLC-DAD method in identifying confiscated peptides and proteins 
using a database, and can be used to identify compounds unknown to the 
database as demonstrated with the small peptide AOD-9604 and the protein 
follistatin.
Furthermore, the presented overview of drug cases between 2007 and 
2013 reveals that the efforts from Danish customs since 2010 has exposed 
drug compounds not previously encountered by our laboratory. Presumably 
these compounds are often bought on the internet.
Figure 7. Chromatogram of tryptic peptides of Follistatin. Each expected tryptic digest is labelled with a “T” followed by its number in the sequence, peptides in 
bold letters were identified by mass. Because of missed trypsin cleavage sites some peptides are also found as a combination of two expected digests, e.g. T5-T6 
is the sequence TELSK-EECCSTGR (where “-“ shows the missed cleavage site)
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